Evidence map›Paper›PMID 42841272›Full record

ArticleMicrobiologyOpen2026

Serial-Passage Assessment Shows No Confirmed Resistance Development to Norway Spruce (Picea Abies) Resin in Bacterial Species Relevant to Wound Infection.

Kamilla Yamileva, Simone Parrotta, Maryam Ghanbarirad, Evgen Multia

Abstract read
In one paragraph

Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kamilla YamilevaRepolar Pharmaceuticals Ltd., Espoo, Finland.
Simone ParrottaRepolar Pharmaceuticals Ltd., Espoo, Finland.ORCID https://orcid.org/0009-0007-8056-2204
Maryam GhanbariradRepolar Pharmaceuticals Ltd., Espoo, Finland.ORCID https://orcid.org/0000-0002-6793-1315
Evgen MultiaDepartment of Bioproducts and Biosystems, School of Chemical Engineering, Aalto University, Espoo, Finland.ORCID https://orcid.org/0000-0002-8717-8842

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for antimicrobials with a low propensity to select resistance has intensified in response to the global antimicrobial resistance crisis. Norway spruce resin (Picea abies) has long been used in Northern European wound care traditions and has shown broad antimicrobial activity in earlier microbiological studies. In the present study, we evaluated whether prolonged exposure to medical-grade spruce resin promotes reduced susceptibility in reference strains of three bacterial species relevant to wound infection. A 20-day serial-passage experiment was performed with Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis using sub-inhibitory resin concentrations and broth microdilution readouts at baseline, Day 10, and Day 20. Resistance development was predefined as a ≥ 4-fold increase in inhibitory concentration. Baseline inhibitory concentrations were 1.25% for S. aureus, 5.0% for P. aeruginosa, and 2.5% for E. faecalis. After 20 days, inhibitory concentrations were 2.5%, 10.0%, and 2.5%, respectively, corresponding to at most twofold changes and remaining below the predefined threshold for resistance development. Validation and vehicle-control arms indicated that these shifts were not attributable to medium transfer or solvent-related bias. These findings suggest that medical-grade Norway spruce resin has a low short-term tendency to select for reduced susceptibility under serial-passage conditions.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEnterococcus faecalisPiceaPseudomonas aeruginosaResins, PlantStaphylococcus aureusHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsResins, Plantantimicrobial resistanceNorway spruce resinPicea abiesreduced susceptibilityserial passagewound‐related bacteria

Identifiers

PMID42841272
PMCPMC13643647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.